![]() | ||
![]() ![]() ![]() | ||
| The combination of adenovirus vector, adjuvant and oral administration will unlock the potential of vector-based vaccination, with applications in Avian Influenza response, second-generation oral versions of existing vaccines, and unmet needs. The company is currently testing an avian flu vaccine in animal models and is seeking financing to initiate a clinical trial in 2009.
Advantages of the Vaxart Vaccine Platform
News October 2008: Vaxart reports demonstration of oral vaccine efficacy against lethal avian flu challenge in ferret and mouse models, at Modern Mucosal Vaccines Adjuvants & Microbicides conference in Portugal. Read more... June 2008: Vaxart presents at BIO International Conference in San Diego. March 2008: Robert Fildes, former President of Biogen and CEO of Cetus, joins Vaxart Board as Chairman. Read more... January 2008: Vaxart profiled in Startup (Windhover publications). November 2007: Vaxart (fka West Coast Biologicals) Completes Series A Financing. Read more... November 2007: NAIAD division of NIH awards $600,000 SBIR grant to Vaxart to develop oral vaccine platform. April 2006: West Coast Biologicals is a finalist in the 2006 Global Life Sciences Innovation Accelerator Competition at UCSF. |
||
| Copyright 2004-2008, Vaxart, Inc. All rights reserved. | ||